Several key enzymes involved in the de novo synthesis pathway, such as ACLY, ACC, and FASN, are significantly up-regulated, suggesting that these enzymes may be potential drug targets for inhibiting cancer progression (Figure 2; Table 2). This evidence concerns the gene ACLY and cancer.